Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Gilead, Aetna sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Infectious Aetna has selected Gileads Harvoni ledipasvir/sofosbuvir to treat HCV genotype 1 infection and Sovaldi …

    Published on 1/26/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious FDA said Victrelis boceprevir from Merck for HCV genotype 1 infection will be discontinued. The small molecule HCV NS3/4A protease inhibitor …

    Published on 1/26/2015
  • AbbVie, Gilead, Harvard Pilgrim Health Care Inc., Humana, Prime Therapeutics LLC sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Harvard Pilgrim Health Care Inc., Wellesley, Mass. Humana Inc. (NYSE:HUM), Louisville, Ky. Prime Therapeutics LLC, St. Paul,…

    Published on 1/19/2015
  • Abbott sales and marketing update

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Infectious Abbott launched Iridica in Europe and other countries that recognize CE Mark approval to identify pathogens causing infections. Iridica can identify…

    Published on 1/12/2015
  • Amarantus BioScience sales and marketing update

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Business: Diagnostic Amarantus launched blood diagnostic LymPro to detect Alzheimers disease (AD). The diagnostic is only available for …

    Published on 1/12/2015
  • Endo sales and marketing update

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Business: Infectious, Generics Endo launched a generic version of Valcyte valganciclovir from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) in the U.S. …

    Published on 1/12/2015
  • Gilead, Anthem, CVS Health sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Anthem Inc. (NYSE:ANTM), Indianapolis, Ind. CVS Health Corp. (NYSE:CVS), Woonsocket, R.I. Business: Infectious CVS Health announced that it would give exclusive …

    Published on 1/12/2015
  • Keryx sales and marketing update

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Business: Renal Keryx launched Auryxia ferric citrate tablets in the U.S. to control serum phosphorus levels in patients with chronic kidney disease (CKD) on …

    Published on 1/12/2015
  • Mylan sales and marketing update

    Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Inflammation, Generics Mylan launched a generic version of Orapred ODT prednisolone from Shionogi & Co. Ltd. (Tokyo:4507, Osaka, Japan) in the U.S. Mylan said its …

    Published on 1/12/2015
  • PerkinElmer sales and marketing update

    PerkinElmer Inc. (NYSE:PKI), Waltham, Mass. Business: Diagnostic PerkinElmer launched VICTOR EnLite and EnLite Neonatal TREC Kit in the U.S. and Canada to detect severe combined immunodeficiency (SCID) in infants. …

    Published on 1/12/2015
  • AbbVie sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious Pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) granted exclusive formulary status to AbbVies Viekira Pak paritaprevir/…

    Published on 1/5/2015
  • Daiichi Sankyo sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Generics, Pharmaceuticals Daiichis Daiichi Sankyo Espha Co. Ltd. subsidiary launched generic versions of levofloxacin, candesartan cilexetil and IV …

    Published on 1/5/2015
  • Dr. Reddys Laboratories Ltd. sales and marketing update

    Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Business: Infectious, Generics Dr. Reddys launched a generic version of valganciclovir tablets in the U.S. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) …

    Published on 1/5/2015
  • Horizon Discovery sales and marketing update

    Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Business: Functional genomics, Biomanufacturing Horizon launched its CHO Source GS -/-cell line worldwide to manufacture therapeutic antibodies. Horizon said it …

    Published on 1/5/2015
  • Ortho-Clinical Diagnostics sales and marketing update

    Ortho-Clinical Diagnostics Inc., Raritan, N.Y. Business: Diagnostic Ortho-Clinical launched the NephroCheck testing system in the U.S. to assess the risk of patients ages 21 years and older developing moderate to severe…

    Published on 1/5/2015
  • Ranbaxy sales and marketing update

    Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Gurgaon, India Business: Infectious Ranbaxy launched malaria drug Synriam arterolane maleate/piperaquine phosphate in Uganda. The company will launch the drug in …

    Published on 1/5/2015
  • Actavis, Debiopharm sales and marketing update

    Actavis plc (NYSE:ACT), Dublin, Ireland Debiopharm Group, Lausanne, Switzerland Business: Generics, Neurology, Cancer Actavis Actavis Specialty Pharmaceuticals Co. subsidiary and Debiopharm launched a six-month dosing …

    Published on 12/22/2014
  • Almac sales and marketing update

    Almac Group Ltd., Craigavon, U.K. Business: Genomics Almac launched a CLIA-validated, next-generation sequencing test for p53 mutations that runs on formalin-fixed, paraffin-embedded (FFPE) samples. The diagnostic has …

    Published on 12/22/2014
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer Amgen launched leukemia drug Blincyto blinatumomab. Blincyto has a wholesale acquisition cost (WAC) of $3,178.57 per single-use vial, or $89,000 for a 28-…

    Published on 12/22/2014
  • CSL sales and marketing update

    CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Other CSL said CMS extended to September 2015 a new technology add-on payment (NTAP) for Kcentra for the urgent reversal of anticoagulation with vitamin K antagonist …

    Published on 12/22/2014
  • Kyowa Hakko Kirin sales and marketing update

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Business: Hematology Kyowa launched G-Lasta pegfilgrastim subcutaneous injection in Japan to decrease the incidence of chemotherapy-associated febrile neutropenia. …

    Published on 12/22/2014
  • Orexigen, Takeda sales and marketing update

    Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic The companies launched Contrave naltrexone/bupropion ER tablets in the U…

    Published on 12/22/2014
  • Personal Genome Diagnostics sales and marketing update

    Personal Genome Diagnostics Inc., Baltimore, Md. Business: Diagnostic Personal Genome launched its CancerSelect targeted gene panel in the U.S., with the exception of Florida and New York, to compare a patients DNA with…

    Published on 12/22/2014
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Infectious Pfizer launched Trumenba in the U.S. to prevent invasive disease caused by Neisseria meningitides serogroup Beta in people ages 10-25. The bivalent …

    Published on 12/22/2014
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cardiovascular Teva launched a generic version of amlodipine/valsartan/hydrochlorothiazide in the U.S. to treat hypertension. Novartis AG (…

    Published on 12/22/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993